The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery

Angela Collarino (Corresponding Author), Renato A. Valdés Olmos, Lotta G.A.J. van Berkel, Peter A. Neijenhuis, Lidy M.H. Wijers, Frederik Smit, Lioe Fee de Geus-Oei, Lenka M. Pereira Arias-Bouda

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)
29 Downloads (Pure)

Abstract

Purpose: To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS). Methods: Following approval by the institutional review board and written informed consent, records of patients with newly diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till December 2014 were retrospectively reviewed. Results: A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9%), with frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54%). In 17 of 287 patients (6%), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 of these additional foci (86%), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 patients (14%), leading to treatment adjustment in 25 patients (9%). Conclusion: MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS.

Original languageEnglish
Pages (from-to)513-522
Number of pages10
JournalBreast cancer research and treatment
Volume169
Issue number3
Early online date13 Feb 2018
DOIs
Publication statusPublished - Jun 2018

Fingerprint

Molecular Imaging
Segmental Mastectomy
Breast
Breast Neoplasms
Mammary Ultrasonography
Neoplasms
Research Ethics Committees
Carcinoma in Situ
Informed Consent
Patient Selection

Keywords

  • UT-Hybrid-D
  • Breast-specific gamma imaging
  • BSGI
  • MBI
  • Molecular breast imaging
  • Preoperative breast imaging
  • Breast cancer

Cite this

Collarino, A., Valdés Olmos, R. A., van Berkel, L. G. A. J., Neijenhuis, P. A., Wijers, L. M. H., Smit, F., ... Pereira Arias-Bouda, L. M. (2018). The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery. Breast cancer research and treatment, 169(3), 513-522. https://doi.org/10.1007/s10549-018-4706-1
Collarino, Angela ; Valdés Olmos, Renato A. ; van Berkel, Lotta G.A.J. ; Neijenhuis, Peter A. ; Wijers, Lidy M.H. ; Smit, Frederik ; de Geus-Oei, Lioe Fee ; Pereira Arias-Bouda, Lenka M. / The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery. In: Breast cancer research and treatment. 2018 ; Vol. 169, No. 3. pp. 513-522.
@article{f6f96912fc1f4182b252e1c281b51207,
title = "The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery",
abstract = "Purpose: To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS). Methods: Following approval by the institutional review board and written informed consent, records of patients with newly diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till December 2014 were retrospectively reviewed. Results: A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9{\%}), with frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54{\%}). In 17 of 287 patients (6{\%}), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 of these additional foci (86{\%}), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 patients (14{\%}), leading to treatment adjustment in 25 patients (9{\%}). Conclusion: MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS.",
keywords = "UT-Hybrid-D, Breast-specific gamma imaging, BSGI, MBI, Molecular breast imaging, Preoperative breast imaging, Breast cancer",
author = "Angela Collarino and {Vald{\'e}s Olmos}, {Renato A.} and {van Berkel}, {Lotta G.A.J.} and Neijenhuis, {Peter A.} and Wijers, {Lidy M.H.} and Frederik Smit and {de Geus-Oei}, {Lioe Fee} and {Pereira Arias-Bouda}, {Lenka M.}",
note = "Springer deal",
year = "2018",
month = "6",
doi = "10.1007/s10549-018-4706-1",
language = "English",
volume = "169",
pages = "513--522",
journal = "Breast cancer research and treatment",
issn = "0167-6806",
publisher = "Springer",
number = "3",

}

Collarino, A, Valdés Olmos, RA, van Berkel, LGAJ, Neijenhuis, PA, Wijers, LMH, Smit, F, de Geus-Oei, LF & Pereira Arias-Bouda, LM 2018, 'The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery' Breast cancer research and treatment, vol. 169, no. 3, pp. 513-522. https://doi.org/10.1007/s10549-018-4706-1

The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery. / Collarino, Angela (Corresponding Author); Valdés Olmos, Renato A.; van Berkel, Lotta G.A.J.; Neijenhuis, Peter A.; Wijers, Lidy M.H.; Smit, Frederik; de Geus-Oei, Lioe Fee; Pereira Arias-Bouda, Lenka M.

In: Breast cancer research and treatment, Vol. 169, No. 3, 06.2018, p. 513-522.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - The clinical impact of molecular breast imaging in women with proven invasive breast cancer scheduled for breast-conserving surgery

AU - Collarino, Angela

AU - Valdés Olmos, Renato A.

AU - van Berkel, Lotta G.A.J.

AU - Neijenhuis, Peter A.

AU - Wijers, Lidy M.H.

AU - Smit, Frederik

AU - de Geus-Oei, Lioe Fee

AU - Pereira Arias-Bouda, Lenka M.

N1 - Springer deal

PY - 2018/6

Y1 - 2018/6

N2 - Purpose: To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS). Methods: Following approval by the institutional review board and written informed consent, records of patients with newly diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till December 2014 were retrospectively reviewed. Results: A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9%), with frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54%). In 17 of 287 patients (6%), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 of these additional foci (86%), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 patients (14%), leading to treatment adjustment in 25 patients (9%). Conclusion: MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS.

AB - Purpose: To investigate the clinical utility of molecular breast imaging (MBI) in patients with proven invasive breast cancer scheduled for breast-conserving surgery (BCS). Methods: Following approval by the institutional review board and written informed consent, records of patients with newly diagnosed breast cancer scheduled for BCS who had undergone MBI for local staging in the period from March 2012 till December 2014 were retrospectively reviewed. Results: A total of 287 women (aged 30–88 years) were evaluated. MBI showed T stage migration in 26 patients (9%), with frequent detection of in situ carcinoma around the tumor. Surgical management was adjusted in 14 of these patients (54%). In 17 of 287 patients (6%), MBI revealed 21 proven additional lesions in the ipsilateral, contralateral breast or both. In 18 of these additional foci (86%), detected in 15 patients, malignancy was found. Thirteen of these 15 patients had ipsilateral cancer and 2 patients bilateral malignancy. In total, MBI revealed a larger tumor extent, additional tumor foci or both in 40 patients (14%), leading to treatment adjustment in 25 patients (9%). Conclusion: MBI seems to be a useful imaging modality with a high predictive value in revealing ipsilateral and bilateral disease not visualized by mammography and ultrasound. It may play an important role in delineating the extent of the index lesion during preoperative planning. Incorporation of MBI in the clinical work-up as an adjunct modality to mammography and ultrasound may lead to better selection of patients who could benefit from BCS.

KW - UT-Hybrid-D

KW - Breast-specific gamma imaging

KW - BSGI

KW - MBI

KW - Molecular breast imaging

KW - Preoperative breast imaging

KW - Breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85041924112&partnerID=8YFLogxK

U2 - 10.1007/s10549-018-4706-1

DO - 10.1007/s10549-018-4706-1

M3 - Article

VL - 169

SP - 513

EP - 522

JO - Breast cancer research and treatment

JF - Breast cancer research and treatment

SN - 0167-6806

IS - 3

ER -